Achillion Pharmaceuticals
ACHN
ACHN was delisted on the 27th of January, 2020.
132 hedge funds and large institutions have $755M invested in Achillion Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 42 funds opening new positions, 32 increasing their positions, 43 reducing their positions, and 31 closing their positions.
88% more capital invested
Capital invested by funds: $402M → $755M (+$352M)
35% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 31
8% more funds holding
Funds holding: 122 → 132 (+10)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
26% less repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 43
62% less call options, than puts
Call options by funds: $30M | Put options by funds: $78.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VI
Versor Investments
New York
|
+$43.5M |
| 2 |
PCM
Pentwater Capital Management
Naples,
Florida
|
+$43.5M |
| 3 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$31.8M |
| 4 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
+$18.3M |
| 5 |
WMSA
Weiss Multi-Strategy Advisers
New York
|
+$16.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$37.9M |
| 2 |
Goldman Sachs
New York
|
-$18.1M |
| 3 |
Millennium Management
New York
|
-$15.9M |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$12M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$10.7M |
ACHN Hedge Fund Activity: Q4 2019 in Review
132 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Achillion Pharmaceuticals (ACHN) for Q4 2019, worth a combined $755M — up 88% from $402M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new ACHN positions and 31 closed out — a net gain of 11 holders — while 32 added to existing stakes and 43 trimmed.
The largest buyer was Versor Investments, opening a new position worth an estimated $43.5M. The largest seller was RTW Investments, cutting an estimated $37.9M.
- 132 institutional investors held Achillion Pharmaceuticals (ACHN) as of Q4 2019, up from 122 in Q3 2019.
- Funds reported $755M of Achillion Pharmaceuticals stock for Q4 2019, up 88% quarter-over-quarter.
- 42 funds opened new Achillion Pharmaceuticals positions in Q4 2019 and 31 closed out, a net change of +11 holders.
- The largest Achillion Pharmaceuticals buyer in Q4 2019 was Versor Investments, an estimated $43.5M added.
- The largest Achillion Pharmaceuticals seller in Q4 2019 was RTW Investments, an estimated $37.9M sold.
Based on aggregated 13F filings for Q4 2019.